Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Mugs your comment on CEO CA

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Aug 17, 2021 9:53am

212 Views

Post# 33716274

RE:RE:Mugs your comment on CEO CA

Thanks Mugs and my applogies for coloring your comments with my view / words.
Well at least mgmt has more than enough data to review from the AME to determine the right next steps. This will be a long wait (Oct) but not much we can do. Thankfully the next steps / analysis is before the height of tax selling so a chance we could see a reversal. One can hope

"During the course of the absorption, metabolism and excretion (“AME”) study, the Company conducted twice-weekly blood draws and collected other specimens to measure key biomarker and pharmacokinetic data. More than 6,200 samples will be analyzed at five specialized labs in Canada and internationally, providing insight on the drug’s behavior and the potential for effectiveness at lower doses."

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages